ReviewFrontiers in immunology2022
Refining the DC-targeting vaccination for preventing emerging infectious diseases.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Thymic APC Networks Orchestrate T-Cell Selection: Mechanisms and Therapeutic Opportunities in Immune Disorders.Immunology · 2026Review
- Dual-targeting oral nanoparticle mucosal vaccine against brucella infection: co-targeting M cells and dendritic cells.Journal of nanobiotechnology · 2026Article
- The Silent Spillover Threat: Nipah Virus Epidemiology, Pathogenesis, Clinical Manifestations, and Advances in Therapeutics and Vaccine Development.Microorganisms · 2026Review
- Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset.bioRxiv : the preprint server for biology · 2026Article
- Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses.EBioMedicine · 2026Article
- Oral Celastrol Nanomedicine Targeting Intestinal Antigen-Presenting Cells to Effectively Mitigate Autoimmune Uveitis via Gut-Retina Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Intranasal DC-targeting vaccine booster elicits durable and cross-clade protective immunity against sarbecoviruses in mice.The Journal of clinical investigation · 2026Article
- Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges.Clinical and experimental medicine · 2026Review
- Neoantigen-driven cancer vaccines in personalized oncology: progress, obstacles, and translational prospects.Molecular biology reports · 2026Review
- Confronting the known unknown: historical lessons and future strategies for Disease X.Frontiers in public health · 2026Review
- Dendritic Cells: Origin, Classification, Development, Biological Functions, and Therapeutic Potential.MedComm · 2025Review
- Dendritic Cells and Their Crucial Role in Modulating Innate Lymphoid Cells for Treating and Preventing Infectious Diseases.Pathogens (Basel, Switzerland) · 2025Review
- Targeting Langerhans cells via skin delivery of HIV Envelope enhances the antibody response to vaccination.NPJ vaccines · 2025Article
- Immune Responses of Dendritic Cells to Zoonotic DNA and RNA Viruses.Veterinary sciences · 2025Review
- Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine.Journal of nanobiotechnology · 2025Article
- Developing T Cell Epitope-Based Vaccines Against Infection: Challenging but Worthwhile.Vaccines · 2025Review
- Oncogenic and Immunological Roles of FRS2 and its Potential Value in Retroperitoneal Liposarcoma: from Bioinformatics Analysis to Clinicopathological Evidence.International journal of medical sciences · 2025Article
- Adjuvant-free, self-assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses.Frontiers in immunology · 2025Article
- T-Cell Epitope-Based Vaccines: A Promising Strategy for Prevention of Infectious Diseases.Vaccines · 2024Review
- A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease.Cell reports. Medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of safe, long-term, effective vaccines is still a challenge for many infectious diseases. Thus, the search of new vaccine strategies and production platforms that allow rapidly and effectively responding against emerging or reemerging pathogens has become a priority in the last years. Targeting the antigens directly to dendritic cells (DCs) has emerged as a new approach to enhance the immune response after vaccination. This strategy is based on the fusion of the antigens of choice to monoclonal antibodies directed against specific DC surface receptors such as CD40. Since time is essential,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.